Zio ECG Utilization Software (ZEUS) System vs Rapid RV/LV

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
by iRhythm Technologies
VS
by RapidAI

AI Verdict

The Zio ECG Utilization Software (ZEUS) System focuses on long-term, continuous ECG monitoring for the detection and management of cardiac arrhythmias, utilizing wearable biosensors and cloud-based analytics. Rapid RV/LV, conversely, is an AI tool designed for the rapid assessment of pulmonary embolism severity by analyzing CTPA imaging scans to measure right and left ventricle ratios. While both fall under the umbrella of Cardiology AI, they address distinct clinical problems using different data modalities (ECG vs. CTPA images) and diagnostic approaches.

Choose Zio ECG Utilization Software (ZEUS) System if…

Choose ZEUS if your primary need is continuous, long-term ECG monitoring for the diagnosis and management of cardiac arrhythmias, leveraging a wearable biosensor and cloud-based AI analytics. This system is ideal for identifying intermittent or elusive arrhythmias over an extended period, providing comprehensive end-of-wear reports for physician review.

View Zio ECG Utilization Software (ZEUS) System →

Choose Rapid RV/LV if…

Choose Rapid RV/LV if you require rapid, AI-powered assessment of pulmonary embolism severity directly from CTPA scans, focusing on automated right and left ventricle ratio measurements. This tool is best suited for acute care settings where quick, objective quantification of ventricular strain is crucial for patient triage and management decisions.

View Rapid RV/LV →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature Zio ECG Utilization Software (ZEUS) System Rapid RV/LV
Pricing Unknown Contact vendor for pricing information.
Deployment Cloud-based. Unknown
BAA Available Yes AI-estimated Yes AI-estimated
FDA Status Yes AI-estimated Cleared AI-estimated
HIPAA Yes AI-estimated Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

Zio ECG Utilization Software (ZEUS) System

Tool A offers a more comprehensive usability experience for both patients and providers, featuring a dedicated patient mobile app for symptom logging and education, alongside a web portal and mobile app for healthcare professionals. This cloud-based approach allows for flexible management and interpretation of reports from various locations, streamlining clinical workflows.

Clinical Value

Tie

Both tools demonstrate significant and validated clinical value in their respective domains. Tool A provides comprehensive, long-term cardiac monitoring with extensive evidence of diagnostic superiority for arrhythmias. Tool B offers rapid, standardized, and prognostically significant assessment for acute pulmonary embolism, aiding in critical triage and decision-making.

Pricing & Value

Zio ECG Utilization Software (ZEUS) System

While both tools require direct vendor contact for pricing, Tool A provides greater transparency regarding insurance coverage with major commercial providers and Medicare, and offers patient financial assistance and payment plans. The presence of established reimbursement codes and a dedicated billing support team suggests a more mature and accessible pricing model for healthcare systems and patients.

Enterprise Readiness

Zio ECG Utilization Software (ZEUS) System

Both tools are FDA-cleared, HIPAA compliant, and offer BAAs, demonstrating strong enterprise readiness. However, Tool A's cloud-based (AWS EC2 platform) and HL7-based EHR integration suggest broader interoperability and scalability within diverse healthcare IT ecosystems. Tool B's on-premises or hybrid deployment, while suitable for some, may involve more local IT overhead.

Innovation

Tie

Both tools apply AI innovatively to critical areas of cardiac care. Tool A's innovation lies in its comprehensive, long-term, continuous ECG monitoring with deep-learned algorithms and integration with wearable biosensors. Tool B's innovation is in its rapid, automated, and standardized assessment of acute pulmonary embolism severity from CTPA imaging, streamlining critical emergency workflows.

Support & Docs

Rapid RV/LV

While both companies provide documentation such as Instructions for Use and reference manuals, RapidAI (Tool B) explicitly offers 24/7/365 customer support via email and phone across multiple countries and languages. This indicates a more robust and transparent support offering compared to the information available for Tool A.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature Zio ECG Utilization Software (ZEUS) System Rapid RV/LV
Name Zio ECG Utilization Software (ZEUS) System Rapid RV/LV
Company iRhythm Technologies RapidAI (formerly iSchemaView)
Primary Function Analyzes continuous ECG data from wearable Zio monitors to aid physicians in the diagnosis and management of cardiac arrhythmias. Rapid assessment of pulmonary embolism severity by automatically measuring right and left ventricle ratios from CTPA scans.
Primary Data Input Continuous ECG data from wearable Zio monitors CTPA scans
Key AI Function AI algorithm for arrhythmia detection and classification; Proprietary deep-learned algorithms for enhanced diagnostic accuracy Automated measurement of right and left ventricle diameters; Calculation of RV/LV ratio
Target Specialties Cardiology, Family Medicine, Internal Medicine Cardiology, Pulmonology, Radiology

Videos

Demos, reviews, and walkthroughs featuring Zio ECG Utilization Software (ZEUS) System and Rapid RV/LV.

Loading videos…
Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

The Zio ECG Utilization Software (ZEUS) System is designed to aid physicians in the diagnosis and management of cardiac arrhythmias by analyzing continuous ECG data from wearable Zio monitors. Rapid RV/LV, on the other hand, is an AI tool for the rapid assessment of pulmonary embolism severity by automatically measuring right and left ventricle ratios from CTPA scans.
ZEUS is a cloud-based platform (AWS EC2) that offers HL7-based EHR integration. Rapid RV/LV can be deployed on-premises (dedicated server or virtual machine) or as a hybrid solution, connecting to the hospital LAN/firewall, and integrates with the broader Rapid PE solution for triage and notification capabilities.
The Zio ECG Utilization Software (ZEUS) System analyzes continuous ECG data collected from Zio wearable biosensors. Rapid RV/LV processes CTPA scan images to perform its analysis and calculate the RV/LV ratio.
ZEUS is primarily intended for use in Cardiology, Family Medicine, and Internal Medicine. Rapid RV/LV is designed for use in Cardiology, Pulmonology, and Radiology.
ZEUS provides comprehensive end-of-wear reports for physician review, accessible via the ZioSuite web portal and mobile application, detailing arrhythmia detection and classification. Rapid RV/LV delivers rapid results within minutes of a scan, including automated measurements of right and left ventricle diameters, calculation of the RV/LV ratio, and annotated images showing these measurements.

Backers

Who funded each tool's parent company.

Zio ECG Utilization Software (ZEUS) System

AI Tool Finder
AI-powered search. Results may not be comprehensive.